Author: Serhat Ertan
Publisher: ERP Destekli Bütçe Danışmanlığı A.Ş.
ISBN:
Category : Business & Economics
Languages : en
Pages : 507
Book Description
This book is the largest referral for Turkish companies.
08 Company Book - DRUG AND MEDICAL DEVICE
Author: Serhat Ertan
Publisher: ERP Destekli Bütçe Danışmanlığı A.Ş.
ISBN:
Category : Business & Economics
Languages : en
Pages : 507
Book Description
This book is the largest referral for Turkish companies.
Publisher: ERP Destekli Bütçe Danışmanlığı A.Ş.
ISBN:
Category : Business & Economics
Languages : en
Pages : 507
Book Description
This book is the largest referral for Turkish companies.
Risk-sharing in the Pharmaceutical Industry
Author: Gerrit Reepmeyer
Publisher: Springer Science & Business Media
ISBN: 379081668X
Category : Business & Economics
Languages : en
Pages : 306
Book Description
The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US$ 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year.
Publisher: Springer Science & Business Media
ISBN: 379081668X
Category : Business & Economics
Languages : en
Pages : 306
Book Description
The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US$ 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year.
Annual Institutional Profile
Author: University of Medicine and Dentistry of New Jersey
Publisher:
ISBN:
Category :
Languages : en
Pages : 314
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages : 314
Book Description
LexisNexis Corporate Affiliations
Vault Career Guide to Pharmaceuticals Sales and Marketing
Author: Carole Moussalli
Publisher: Vault Inc.
ISBN: 1581313861
Category : Career education
Languages : en
Pages : 201
Book Description
Get the inside scoop on pharmaceutical sales careers with this new Vault Guide. Overview of the industry; functions in pharmaceutical sales: field sales, sales management, training and development, instructional design/content development, project management; jobs and career paths; getting hired - education, interview preparation, and more.
Publisher: Vault Inc.
ISBN: 1581313861
Category : Career education
Languages : en
Pages : 201
Book Description
Get the inside scoop on pharmaceutical sales careers with this new Vault Guide. Overview of the industry; functions in pharmaceutical sales: field sales, sales management, training and development, instructional design/content development, project management; jobs and career paths; getting hired - education, interview preparation, and more.
Transforming Big Pharma
Author: John Ansell
Publisher: CRC Press
ISBN: 1317007719
Category : Business & Economics
Languages : en
Pages : 242
Book Description
In Transforming Big Pharma John Ansell addresses critically how strategy works in the pharmaceutical industry. The long-standing dearth of new products has led to a growing shortfall in revenues. Ansell assesses the wide range of alternative strategies big pharma companies have been pursuing in recent years in attempting to overcome this. He shows that there is sound evidence to expect the recent upturn in the number of new products reaching the market to go on to greater heights. Chapters assess the complex trends in attrition rates, show how rife spectacular sales underestimation in the industry remains, and explain how conventional wisdom on the chances of product profitability also seriously undersells the industry. The surest route to transforming the prospects for big pharma, Ansell contends, is to step up activity in acquiring and developing new products. This is now realistic because, as he shows, the amount of intellectual property available is much greater than it was a decade ago. Ansell believes that no other strategies have sufficient transformative powers, though they may be useful as a stopgap whilst the sales of forthcoming new products mature. He argues for a reversal of big pharma’s recent cutbacks in R&D and licensing, and re-focussing on new product development. Transforming Big Pharma is intended for those in senior and middle management in the pharmaceutical industry. It will also be valuable to students, as well as to all those dealing with the industry, including biotech companies and those providing services and products to the pharmaceutical industry.
Publisher: CRC Press
ISBN: 1317007719
Category : Business & Economics
Languages : en
Pages : 242
Book Description
In Transforming Big Pharma John Ansell addresses critically how strategy works in the pharmaceutical industry. The long-standing dearth of new products has led to a growing shortfall in revenues. Ansell assesses the wide range of alternative strategies big pharma companies have been pursuing in recent years in attempting to overcome this. He shows that there is sound evidence to expect the recent upturn in the number of new products reaching the market to go on to greater heights. Chapters assess the complex trends in attrition rates, show how rife spectacular sales underestimation in the industry remains, and explain how conventional wisdom on the chances of product profitability also seriously undersells the industry. The surest route to transforming the prospects for big pharma, Ansell contends, is to step up activity in acquiring and developing new products. This is now realistic because, as he shows, the amount of intellectual property available is much greater than it was a decade ago. Ansell believes that no other strategies have sufficient transformative powers, though they may be useful as a stopgap whilst the sales of forthcoming new products mature. He argues for a reversal of big pharma’s recent cutbacks in R&D and licensing, and re-focussing on new product development. Transforming Big Pharma is intended for those in senior and middle management in the pharmaceutical industry. It will also be valuable to students, as well as to all those dealing with the industry, including biotech companies and those providing services and products to the pharmaceutical industry.
Kucers' The Use of Antibiotics
Author: M. Lindsay Grayson
Publisher: CRC Press
ISBN: 1498747965
Category : Medical
Languages : en
Pages : 4894
Book Description
Kucers’ The Use of Antibiotics is the definitive, internationally-authored reference, providing everything that the infectious diseases specialist and prescriber needs to know about antimicrobials in this vast and rapidly developing field. The much-expanded Seventh Edition comprises 4800 pages in 3 volumes in order to cover all new and existing therapies, and emerging drugs not yet fully licensed. Concentrating on the treatment of infectious diseases, the content is divided into four sections - antibiotics, anti-fungal drugs, anti-parasitic drugs, and anti-viral drugs - and is highly structured for ease of reference. Each chapter is organized in a consistent format, covering susceptibility, formulations and dosing (adult and pediatric), pharmacokinetics and pharmacodynamics, toxicity, and drug distribution, with detailed discussion regarding clinical uses - a feature unique to this title. Compiled by an expanded team of internationally renowned and respected editors, with expert contributors representing Europe, Africa, Asia, Australia, South America, the US, and Canada, the Seventh Edition adopts a truly global approach. It remains invaluable for anyone using antimicrobial agents in their clinical practice and provides, in a systematic and concise manner, all the information required when prescribing an antimicrobial to treat infection.
Publisher: CRC Press
ISBN: 1498747965
Category : Medical
Languages : en
Pages : 4894
Book Description
Kucers’ The Use of Antibiotics is the definitive, internationally-authored reference, providing everything that the infectious diseases specialist and prescriber needs to know about antimicrobials in this vast and rapidly developing field. The much-expanded Seventh Edition comprises 4800 pages in 3 volumes in order to cover all new and existing therapies, and emerging drugs not yet fully licensed. Concentrating on the treatment of infectious diseases, the content is divided into four sections - antibiotics, anti-fungal drugs, anti-parasitic drugs, and anti-viral drugs - and is highly structured for ease of reference. Each chapter is organized in a consistent format, covering susceptibility, formulations and dosing (adult and pediatric), pharmacokinetics and pharmacodynamics, toxicity, and drug distribution, with detailed discussion regarding clinical uses - a feature unique to this title. Compiled by an expanded team of internationally renowned and respected editors, with expert contributors representing Europe, Africa, Asia, Australia, South America, the US, and Canada, the Seventh Edition adopts a truly global approach. It remains invaluable for anyone using antimicrobial agents in their clinical practice and provides, in a systematic and concise manner, all the information required when prescribing an antimicrobial to treat infection.
Plunkett's Health Care Industry Almanac 2008
Author: Jack W. Plunkett
Publisher: Plunkett Research, Ltd.
ISBN: 1593920962
Category : Medical economics
Languages : en
Pages : 732
Book Description
Offers a market research guide to the American health care industry - a tool for strategic planning, competitive intelligence, employment searches or financial research. This book covers national health expenditures, technologies, patient populations, research, Medicare, Medicaid, and managed care.
Publisher: Plunkett Research, Ltd.
ISBN: 1593920962
Category : Medical economics
Languages : en
Pages : 732
Book Description
Offers a market research guide to the American health care industry - a tool for strategic planning, competitive intelligence, employment searches or financial research. This book covers national health expenditures, technologies, patient populations, research, Medicare, Medicaid, and managed care.
International Directory of Company Histories
The Journal of Biolaw & Business
Author:
Publisher:
ISBN:
Category : Biotechnology industries
Languages : en
Pages : 404
Book Description
Publisher:
ISBN:
Category : Biotechnology industries
Languages : en
Pages : 404
Book Description